MGTX News and Press, MeiraGTx Holdings plc From 10/04/22

LONDON and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit 15 poster presentations at the European Society of Gene and Cell Therapy (ESGCT)...

LONDON and NEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical-stage gene therapy company, announced today the primary results from the Phase 1/2 study evaluating the investigational gene therapy botaretigene...

-- Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization -- Site reflects MeiraGTx’s unique, end-to-end approach to gene th...

LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the follow...

MeiraGTx press release ( NASDAQ: MGTX ): Q2 GAAP EPS of -$0.76. Revenue of $10.76M (+110.6% Y/Y). For further details see: MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Quarter 2024 LONDON and NEW ...

MeiraGTx Holdings ( NASDAQ: MGTX ) traded higher on Wednesday after the gene therapy company announced a term loan agreement with affiliates of Perceptive Advisors for up to $100M collateralized by its production plants in London, U.K., and Shannon, Ireland. With the closi...

- Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing strengthens balance sheet and extends runway to fourth quarter of 2024 LONDON and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIR...

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were demonstrated in multiple different endpoints in botaretigene sparoparvovec-treated pati...

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event. For further details see: MeiraGTx (MGTX) Investor Presentation - Slideshow